14-day Premium Trial Subscription Sign Up For FreeGet Free

Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

$208.56 (-0.35%)

Volume: 405k

Closed: Oct 15, 2021

Hollow Logo Score: 1.824

Alnylam Pharmaceuticals Stock Forecast

$208.56 (-0.35%)

Volume: 405k

Closed: Oct 15, 2021

Score Hollow Logo 1.824

Alnylam Pharmaceuticals Stock News NASDAQ:ALNY

Allstate Closes Sale of New York Life and Annuity Businesses

03:41pm, Friday, 01'st Oct 2021 Business Wire
NORTHBROOK, Ill.--(BUSINESS WIRE)--The Allstate Corporation (NYSE: ALL) today announced that it has obtained all required regulatory approvals and closed the sale of Allstate Life Insurance Company of New York (ALNY) to Wilton Re for approximately $400 million. Closing on the sale of ALNY is a significant step in Allstates strategy of increasing personal property-liability market share and expanding protection services, while deploying capital out of the life and annuity businesses, said Mar Read more
The report begins with the overview of the Gene Delivery System Technology Drug Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and Read more
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after t Read more

Novartis AG Consensus Indicates Potential 26.6% Upside

09:42am, Friday, 24'th Sep 2021 DirectorsTalk
Novartis AG with ticker code (NVS) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 108 and 100 with the average target price sitting at 104.8. With the stocks previous close at 82.8 this is indicating there is a potential upside of 26.6%. The 50 day moving average now sits at 89.97 while the 200 day moving average is 89.3. The market capitalisation for the company is $187,269m. Find out more information at: /> [stock_market_widget type="chart" symbol="NVS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. Read more
(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with Read more
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. “hATTR amyloidosis is a rare, rapidly progressive, debilitating and fatal condition and we are d Read more

Novartis AG Consensus Indicates Potential 18.0% Upside

09:06am, Friday, 10'th Sep 2021 DirectorsTalk
Novartis AG with ticker code (NVS) now have 6 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 108 and 96 and has a mean target at 103.33. Given that the stocks previous close was at 87.57 this is indicating there is a potential upside of 18.0%. The day 50 moving average is 92.15 and the 200 day moving average is 89.46. The market cap for the company is $194,945m. Company Website: /> [stock_market_widget type="chart" symbol="NVS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. Read more
PNH and aHUS Market Research Report 2021 - 2027 Latest released, the research study on Global PNH and aHUS Market Report Forecast 2021 - 2027, offers a detailed overview of the factors influencing the global business scope. PNH and aHUS Market Read more
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 pm ET H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 7:00 am ET BofA Global Healthcare Conference on Thursday, September 16, 20 Read more
Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, underdiagnosed, inherited, rapidly progressive, debilitating, and often fatal condition. It is caused by variants (i.e., mutations) in the transthyretin (TTR) gene. hATTR amyloidosis symptoms can vary from person to person, depending on which organs Read more
Alpha-1 antitrypsin deficiency (AATD) is an inherited disease that causes an increased risk of having chronic obstructive pulmonary disease (COPD), liver disease, skin problems (panniculitis), and inflammation of the blood vessels (vasculitis). Alpha-1 antitrypsin deficiency occurs worldwide, but its prevalence varies Read more
Small interfering RNA (siRNA) is a sort of genetic medication that has the ability to mute or inhibit any disease-causing gene. Short interfering RNA is another name for it. Apoptosis, insulin signaling, cytokinesis, and cell differentiation are among the biological Read more
Related Stocks: ALNY , Read more
Related Stocks: VRTX , ABNB , TMUS , CMI , FTCH , SUPN , ALNY , CRSP , SM , OXM , CIEN , INGN , FORM , GSHD , GWPH , EGOV , ATSG , CCXI , Read more
LP INFORMATION recently released a research report on the Alpha- Antitrypsin Deficiency Treatment analysis, which studies the Alpha- Antitrypsin Deficiency Treatment industry coverage, current market competitive status, and market outlook and forecast by 2026. Global Alpha- Antitrypsin Deficiency Treatment Market 2021-2026 Research Report categorizes the global Alpha- Antitrypsin Deficiency Treatment by key players, product type, applications and regions,etc. The [] Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE